Targeting specific proteins to treat multiple myeloma
Targeting chromatin acetylation factors in multiple myeloma
This study is looking at new ways to treat multiple myeloma by targeting certain proteins that help the cancer cells grow, and it’s designed for people who are affected by this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11046875 on NIH RePORTER |
What this research studies
This research focuses on multiple myeloma, a type of cancer that affects plasma cells in the blood. The team is developing new chemical tools that can degrade specific proteins, known as CBP and p300, which are crucial for the growth and survival of myeloma cells. By using advanced techniques to study how these proteins can be targeted, the researchers aim to find more effective treatment strategies. The project will involve laboratory experiments and animal models to test the effectiveness of these new treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with multiple myeloma, particularly those who have not responded well to existing treatments.
Not a fit: Patients with other types of cancer or those who do not have multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with multiple myeloma, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in targeting chromatin regulators for cancer treatment, suggesting that this approach may be effective.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Ott, Christopher J — Massachusetts General Hospital
- Study coordinator: Ott, Christopher J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.